Novartis 1Q Revenues: $11.1 billion (+2%) 1Q Earnings: $1.8 billion (-13%) Comments: Growth was driven by Cosentyx ($791 million, +36%), Entresto ($357 million, +79%), Lutathera (sales of $106 million), Promacta ($307 million, +19%) and Kisqali (sales of $91 million), partly offset by the negative impacts of pricing and generic competition. Tasigna sales were down 7% to $434 million. Sandostatin sales were down 2% to $392 million. Gleevec sales were down 22% to $307 million. Exjade sales were...